Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of 7HP349 in Healthy Men
NCT04508179Phase 1Completed
- Sponsor
- 7 Hills Pharma
- Start
- Oct 2020
- Primary completion
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in solid tumor comparing 7HP349 Capsules with Placebo Capsules (2 arms). Primary endpoint: Incidence of treatment-emergent adverse events according to CTCAE v5.0 criteria at 17 days. Started Oct 2020; status: completed.
02
Drugs
alintegimod
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT04508179.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04508179.